Literature DB >> 29217605

Care pathways for the selection of a biologic in severe asthma.

Jean Bousquet1,2,3, Guy Brusselle4, Roland Buhl5, William W Busse6, Alvaro A Cruz7,8, Ratko Djukanovic9, Christian Domingo10, Nicola A Hanania11, Marc Humbert12, Andrew Menzies Gow13, Wanda Phipatanakul14, Ulrich Wahn15, Michael E Wechsler16.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29217605     DOI： 10.1183/13993003.01782-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  14 in total

1.  Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives.

Authors:  Salman Siddiqui; Loren C Denlinger; Stephen J Fowler; Praveen Akuthota; Dominick E Shaw; Liam G Heaney; Louise Brown; Mario Castro; Tonya A Winders; Monica Kraft; Scott Wagers; Michael C Peters; Ian D Pavord; Samantha Walker; Nizar N Jarjour
Journal:  Am J Respir Crit Care Med       Date:  2019-04-01       Impact factor: 21.405

2.  The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children.

Authors:  Mohamed S Al-Moamary; Sami A Alhaider; Abdullah A Alangari; Mohammed O Al Ghobain; Mohammed O Zeitouni; Majdy M Idrees; Abdullah F Alanazi; Adel S Al-Harbi; Abdullah A Yousef; Hassan S Alorainy; Mohamed S Al-Hajjaj
Journal:  Ann Thorac Med       Date:  2019 Jan-Mar       Impact factor: 2.219

3.  Beliefs and preferences regarding biological treatments for severe asthma.

Authors:  Andras Bikov; Ipek Kivilcim Oğuzülgen; Ilaria Baiardini; Marco Contoli; Alexander Emelyanov; Omar Fassio; Juan Carlos Ivancevich; Igor Kaidashev; Krzysztof Kowal; Marina Labor; Lies Lahousse; Stefan Mihaicuta; Silviya Novakova; Alicia Padilla Galo; Alexander Simidchiev; Angelica Tiotiu; Ignacio J Ansotegui; Jonathan A Bernstein; Louis Philippe Boulet; Giorgio Walter Canonica; Lawrence Dubuske; Nelson Rosario; Pierachille Santus; Fulvio Braido
Journal:  World Allergy Organ J       Date:  2020-07-31       Impact factor: 4.084

4.  Dual Monoclonal Antibody Therapy for a Severe Asthma Patient.

Authors:  Christian Domingo; Xavier Pomares; Anisi Morón; Ana Sogo
Journal:  Front Pharmacol       Date:  2020-09-30       Impact factor: 5.810

Review 5.  Taming Asthma in School-Aged Children: A Comprehensive Review.

Authors:  Ahmad Salaheddine Naja; Perdita Permaul; Wanda Phipatanakul
Journal:  J Allergy Clin Immunol Pract       Date:  2018 May - Jun

Review 6.  Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.

Authors:  Corrado Pelaia; Cecilia Calabrese; Rosa Terracciano; Francesco de Blasio; Alessandro Vatrella; Girolamo Pelaia
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

Review 7.  Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.

Authors:  Rosalia Emma; Jaymin B Morjaria; Virginia Fuochi; Riccardo Polosa; Massimo Caruso
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

Review 8.  Severe Asthma and Biological Therapy: When, Which, and for Whom.

Authors:  Paola Rogliani; Luigino Calzetta; Maria Gabriella Matera; Rossella Laitano; Beatrice Ludovica Ritondo; Nicola A Hanania; Mario Cazzola
Journal:  Pulm Ther       Date:  2019-12-26

9.  Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.

Authors:  Giovanna Elisiana Carpagnano; Corrado Pelaia; Maria D'Amato; Nunzio Crimi; Nicola Scichilone; Giulia Scioscia; Onofrio Resta; Cecilia Calabrese; Girolamo Pelaia; Carla Maria Irene Quarato; Maria Pia Foschino Barbaro
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

10.  Bronchoscopy-guided bronchial epithelium sampling as a tool for selecting the optimal biologic treatment in a patient with severe asthma: a case report.

Authors:  Chin-Wei Kuo; Xin-Min Liao; Yi-Ching Huang; Han-Yu Chang; Chi-Chang Shieh
Journal:  Allergy Asthma Clin Immunol       Date:  2019-11-27       Impact factor: 3.406
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.